SAVA

Insider Trades

Name	Value	Action	Price	Current Price
Anderson Robert Eugene JrDirector $25k8.6k shares BuyNov 24, 2025 $2.90 --
Barry RichardDirector, Officer: President & CEO $414k150k shares BuyNov 20, 2025 $2.76 --
Barry RichardDirector, Officer: President & CEO $202k73.4k shares BuyNov 19, 2025 $2.75 --
Cook Robert ChristopherChief Operating & Legal Office $40k13.7k shares BuySep 30, 2025 $2.91 --
Barry RichardDirector, Officer: President & CEO $16k7.2k shares BuySep 22, 2025 $2.28 --
Barry RichardDirector, Officer: President & CEO $900400 shares BuySep 19, 2025 $2.25 --

Trade SAVA

About Cassava Sciences, Inc.

Cassava Sciences, Inc. is a biopharmaceutical enterprise in the clinical development phase, specializing in the creation of treatments for neurodegenerative disorders. The company's primary experimental drug, simufilam, a small-molecule compound, has successfully concluded its Phase 2b clinical trials. In parallel, they are advancing SavaDx, an investigational blood-based biomarker test designed to aid in the detection of Alzheimer's disease. Established in 1998 and headquartered in Austin, Texas, the company underwent a name change in March 2019, previously operating as Pain Therapeutics, Inc.

CEO: Richard Jon Barry
IPO Date: Jul 14, 2000

Market Data

Open: $1.30
High: $1.35
Low: $1.27
Volume: 134.3K
Avg Volume: 857.8K
52W High: $4.98
52W Low: $1.15

Valuation

Market Cap: $64M
Enterprise Value: $-28M
Dividend Yield: 0.00%

Financials

Free Cash Flow: $-33M
Revenue: $0
Net Income: $-91M
Cash: $96M
Debt: $0

Events

EarningsMar 12

EPS est. -0.3 · actual -0.25962